Abstract
Background: Central diabetes insipidus (DI) is a rare disorder in children caused by a deficiency of antidiuretic hormone arginine (vasopressin). Desmopressin is the first line agent in management of central DI. However, one of the side effects of desmopressin is water intoxication and hyponatraemia. This study reviews the patterns of desmopressin use and side effects in our institution.
Methods: Retrospective chart review of all patients with central DI followed up in one tertiary centre between 1 January 2008 and 31 December 2010.
Results: Forty-one patients (22 males and 19 females) were included. Twelve patients (29.3%) had congenital and 29 patients (70.7%) had acquired DI, mostly as a result of intracranial tumours. Thirty-six (87.8%) patients were on oral desmopressin and the remaining on nasal formulation. The median oral dose was 9.5 (4.2–17.0) μg/kg/day with median frequency of 2.5 (2–3). The median nasal dose was 0.7 (0.4–1.4) μg/kg/day with median frequency of 2.0 (2–3.5). Fourteen patients (34.1%) were switched from nasal to oral desmopressin with the median dose conversion factor of 20.1 (10.7–31.8). Forty percent of patients on nasal desmopressin experienced hypo/hypernatraemia compared to 18.1% on oral, however, there were no significance difference between standardized hypo/hypernatraemia episodes per treatment year.
Conclusions: Oral desmopressin is used in the majority of our patients including infants and toddlers. There is wide inter-individual variation in dose requirement and dosing intervals. Management of central diabetes insipidus remains a challenge in adipsic patients and in young children during intercurrent illness regardless of the desmopressin formulation.
This research was approved by the Sydney Children’s Hospitals Network Human Research Ethics Committee.
References
1. Maghnie M, Cosi G, Genovese E, Manca-Bitti ML, Cohen A, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000;343:998–1007.10.1056/NEJM200010053431403Search in Google Scholar PubMed
2. Westgren U, Wittstrom C, Harris AS. Oral desmopressin in central diabetes insipidus. Arch Dis Child 1986;61:247–50.10.1136/adc.61.3.247Search in Google Scholar PubMed PubMed Central
3. Mishra G, Chandrashekhar SR. Management of diabetes insipidus in children. Indian J Endocrinol Metab 2011; 15(Suppl 3):180–7.10.4103/2230-8210.84858Search in Google Scholar PubMed PubMed Central
4. Kim RJ, Malattia C, Allen M, Moshang T Jr, Maghnie M. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev 2004;2(Suppl 1):115–23.Search in Google Scholar
5. Di Iorgi N, Napoli F, Allegri AE, Olivieri I, Bertelli E, et al. Diabetes insipidus–diagnosis and management. Horm Res Paediatr 2012;77:69–84.10.1159/000336333Search in Google Scholar PubMed
6. Williams TD, Dunger DB, Lyon CC, Lewis RJ, Taylor F, et al. Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. J Clin Endocrinol Metab 1986;63:129–32.10.1210/jcem-63-1-129Search in Google Scholar PubMed
7. Vande Walle J, Stockner M, Raes A, Norgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007;2:232–8.10.2174/157488607781668891Search in Google Scholar PubMed
8. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol 2007;178:24–30.10.1016/j.juro.2007.03.015Search in Google Scholar PubMed
9. Toumba M, Stanhope R. Morbidity and mortality associated with vasopressin analogue treatment. J Pediatr Endocrinol Metab 2006;19:197–201.10.1515/JPEM.2006.19.3.197Search in Google Scholar PubMed
10. Greger NG, Kirkland RT, Clayton GW, Kirkland JL. Central diabetes insipidus. 22 years’ experience. Am J Dis Child 1986;140:551–4.10.1001/archpedi.1986.02140200061028Search in Google Scholar PubMed
11. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;246: 1–190.Search in Google Scholar
12. Fjellestad A, Czernichow P. Central diabetes insipidus in children. V. Oral treatment with a vasopressin hormone analogue (DDAVP). Acta Paediatr Scand 1986;75: 605–10.10.1111/j.1651-2227.1986.tb10259.xSearch in Google Scholar PubMed
13. Rittig S, Jensen AR, Jensen KT, Pedersen EB. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998;48:235–41.10.1046/j.1365-2265.1998.00340.xSearch in Google Scholar
14. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf) 1993;38:177–82.10.1111/j.1365-2265.1993.tb00990.xSearch in Google Scholar
15. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103:228–39.10.7326/0003-4819-103-2-228Search in Google Scholar
16. Fjellestad A, Rappaport R, Czernichow P. Oral treatment of central diabetes insipidus (DI) in children by DDAVP tablets. Pediatr Res 1985;19:604.10.1203/00006450-198506000-00027Search in Google Scholar
17. Stick SM, Betts PR. Oral desmopressin in neonatal diabetes insipidus. Arch Dis Child 1987;62:1177–8.10.1136/adc.62.11.1177Search in Google Scholar
18. Adverse Drug Reactions Advisory Committee (ADRAC) and the Adverse Drug Reactions Unit (ADRU) of the TGA. Desmopressin and hyponatraemia. Aust Adv Drug Reactions Bull 2008;27:15.Search in Google Scholar
19. Fjellestad-Paulsen A, Tubiana-Rufi N, Harris A, Czernichow P. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Acta Endocrinol (Copenh) 1987;115:307–12.10.1530/acta.0.1150307Search in Google Scholar
20. Fukuda I, Hizuka N, Takano K. Oral DDAVP is a good alternative therapy for patients with central diabetes insipidus: experience of five-year treatment. Endocr J 2003;50:437–43.10.1507/endocrj.50.437Search in Google Scholar
21. Murphy I. Minirin dose equivalence. In: Chin C, editor. Pymble, Australia: Ferring Pharmaceuticals, 2003.Search in Google Scholar
22. Thumfart J, Roehr CC, Kapelari K, Querfeld U, Eggert P, et al. Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors? J Urol 2005;174:294–8.Search in Google Scholar
23. Argenti D, Ireland D, Heald DL. A pharmacokinetic and pharmacodynamic comparison of desmopressin administered as whole, chewed and crushed tablets, and as an oral solution. J Urol 2001;165:1446–51.10.1016/S0022-5347(05)66325-2Search in Google Scholar
24. Blanco EJ, Lane AH, Aijaz N, Blumberg D, Wilson TA. Use of subcutaneous DDAVP in infants with central diabetes insipidus. J Pediatr Endocrinol Metab 2006;19:919–25.10.1515/JPEM.2006.19.7.919Search in Google Scholar PubMed
25. Rivkees SA, Dunbar N, Wilson TA. The management of central diabetes insipidus in infancy: desmopressin, low renal solute load formula, thiazide diuretics. J Pediatr Endocrinol Metab 2007;20:459–69.10.1515/JPEM.2007.20.4.459Search in Google Scholar PubMed
26. Ball SG, Vaidja B, Baylis PH. Hypothalamic adipsic syndrome: diagnosis and management. Clin Endocrinol (Oxf) 1997;47:405–9.10.1046/j.1365-2265.1997.2591079.xSearch in Google Scholar PubMed
27. Crowley RK, Sherlock M, Agha A, Smith D, Thompson CJ. Clinical insights into adipsic diabetes insipidus: a large case series. Clin Endocrinol (Oxf) 2007;66:475–82.10.1111/j.1365-2265.2007.02754.xSearch in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston